Meeting
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
Authors
Michal Sternschuss
Memorial Sloan Kettering Cancer Center, New York, NY
Michal Sternschuss , Brendan John Guercio , Eugene J. Pietzak , Maria Ponomarev , Ashley M. Regazzi , Colleen Quinlan , David H Aggen , Alvin C. Goh , Eugene K. Cha , S. Machele Donat , A. Ari Hakimi , Richard Matulewicz , Samuel A Funt , Dean F. Bajorin , Gopa Iyer , Irina Ostrovnaya , Hikmat A. Al-Ahmadie , Jonathan E. Rosenberg , Jonathan Coleman , Min Yuen Teo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03520491
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 645)
DOI
10.1200/JCO.2024.42.4_suppl.645
Abstract #
645
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).
First Author: Min Yuen Teo
Poster
2023 ASCO Annual Meeting
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
First Author: Hailiang Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.
First Author: Hong Truong
Poster
2024 ASCO Annual Meeting
Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB).
First Author: Kit L. Yuen